Acute Leukemia CPG Mini Module - CAR T Cell Therapy for Acute Lymphocytic Leukemia in Adults
The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.
Jorge Cortes, MD - Georgia Cancer Center opens this module with a case presentation of a patient with relapsed/refractory acute lymphocytic leukemia (R/R ALL). This presentation includes past options for treating R/R ALL, clinical data supporting the recent approval of CAR T-cell therapy for treating R/R ALL, and the management of adverse events associated wi th CAR T-cell therapy. The module ends with a discussion between Dr. Cortes and Dr. Steven Gore - National Cancer Institute, Maryland regarding alternate approaches and additional considerations when treating patients with R/R ALL.
Run time: 13 minutes 21 seconds
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021).
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.